Lack of efficacy of drug therapy in preventing takotsubo cardiomyopathy recurrence: A meta-analysis

Clinical Cardiology

Volumn 37, Issue 7, 2014, Pages 434-439

  Santoro, Francesco ^a   Ieva, Riccardo ^a   Musaico, Francesco ^a   Ferraretti, Armando ^a   Triggiani, Giuseppe ^a   Tarantino, Nicola ^a   Biase, Matteo Di ^a   Brunetti, Natale Daniele ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARDIOVASCULAR AGENT;

CLINICAL EFFECTIVENESS; DRUG TREATMENT FAILURE; HEART PROTECTION; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; TAKOTSUBO CARDIOMYOPATHY; PROCEDURES; RISK; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; TIME; TREATMENT OUTCOME;

CARDIOVASCULAR AGENTS; HUMANS; ODDS RATIO; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TAKOTSUBO CARDIOMYOPATHY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904765175     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22280     Document Type: Review

References (28)

1. Song BG, Yang HS, Hwang HK, et al. The impact of stressor patterns on clinical features in patients with tako-tsubo cardiomyopathy: experiences of two tertiary cardiovascular centers. Clin Cardiol. 2012; 35: E6-E13.
2. Bybee KA, Prasad A,. Stress-related cardiomyopathy syndromes. Circulation. 2008; 118: 397-409.
3. Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005; 352: 539-548.
4. Dote K, Sato H, Tateishi H, et al. Myocardial stunning due to simultaneous multivessel coronary spasms: a review of 5 cases [article in Japanese]. J Cardiol. 1991; 21: 203-214.
5. Jain M, Upadaya S, Zarich SW,. Serial evaluation of microcirculatory dysfunction in patients with Takotsubo cardiomyopathy by myocardial contrast echocardiography. Clin Cardiol. 2013; 36: 531-534.
6. Madhavan M, Rihal CS, Lerman A, et al. Acute heart failure in apical ballooning syndrome (TakoTsubo/stress cardiomyopathy): clinical correlates and Mayo Clinic risk score. J Am Coll Cardiol. 2011; 57: 1400-1401.
7. Parodi G, Bellandi B, Del Pace S, et al. Tuscany Registry of Tako-Tsubo Cardiomyopathy. Natural history of tako-tsubo cardiomyopathy. Chest. 2011; 139: 887-892.
8. Sharkey SW, Windenburg DC, Lesser JR, et al. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol. 2010; 55: 333-341.
9. Elesber AA, Prasad A, Lennon RJ, et al. Four-year recurrence rate and prognosis of the apical ballooning syndrome. J Am Coll Cardiol. 2007; 50: 448-452.
10. Wilczynski NL, Haynes RB,; Hedges Team. Developing optimal search strategies for detecting clinically sound prognostic studies in MEDLINE: an analytic survey. BMC Med. 2004; 2: 23.
11. Prasad A, Lerman A, Rihal CS,. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008; 155: 408-417.
12. Cacciotti L, Passaseo I, Marazzi G, et al. Observational study on Takotsubo-like cardiomyopathy: clinical features, diagnosis, prognosis and follow-up. BMJ Open. 2012; 2: e001165.
13. Opolski G, Pawlak MM, Roik MF, et al. Clinical presentation, treatment, and long-term outcomes in patients with takotsubo cardiomyopathy: experience of a single cardiology center. Pol Arch Med Wewn. 2010; 120: 231-236.
14. Brenner R, Weilenmann D, Maeder MT, et al. Clinical characteristics, sex hormones, and long-term follow-up in Swiss postmenopausal women presenting with Takotsubo cardiomyopathy. Clin Cardiol. 2012; 35: 340-347.
15. Looi JL, Wong CW, Khan A, et al. Clinical characteristics and outcome of apical ballooning syndrome in Auckland, New Zealand. Heart Lung Circ. 2012; 21: 143-149.
16. Samardhi H, Raffel OC, Savage M, et al. Takotsubo cardiomyopathy: an Australian single-centre experience with medium-term follow-up. Intern Med J. 2012; 42: 35-42.
17. Kurisu S, Inoue I, Kawagoe T, et al. Assessment of medications in patients with tako-tsubo cardiomyopathy. Int J Cardiol. 2009; 134: e120-e123.
18. Venditti F, Bellandi B, Parodi G,. Fatal Tako-Tsubo cardiomyopathy recurrence after β2-agonist administration. Int J Cardiol. 2012; 161: e10-e11.
19. Mendoza I, Novaro GM,. Repeat recurrence of takotsubo cardiomyopathy related to inhaled β-2-adrenoceptor agonists. World J Cardiol. 2012; 4: 211-213.
20. Paur H, Wright PT, Sikkel MB, et al. High levels of circulating epinephrine trigger apical cardiodepression in a β2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy. Circulation. 2012; 126: 697-706.
21. Kawano H, Okada R, Yano K,. Histological study on the distribution of autonomic nerves in the human heart. Heart Vessels. 2003; 18: 32-39.
22. Santoro F, Ieva R, Spennati G, et al. Tako-Tsubo cardiomyopathy in a teen girl with pheochromocytoma. Int J Cardiol. 2012; 160: e48-e49.
23. Gong H, Sun H, Koch WJ, et al. The specific β(2)AR blocker ICI 118 551 actively decreases contraction through a G(i)-coupled form of the β(2)AR in myocytes from failing human heart. Circulation. 2002; 105: 2497-2503.
24. Palla AR, Dande AS, Petrini J, et al. Pretreatment with low-dose β-adrenergic antagonist therapy does not affect severity of Takotsubo cardiomyopathy. Clin Cardiol. 2012; 35: 478-481.
25. Ieva R, Santoro F, Ferraretti A, et al. Hyper-acute precipitating mechanism of Tako-Tsubo cardiomyopathy: in the beginning was basal hyperkinesis? Int J Cardiol. 2013; 167: e55-e57.
26. Santoro F, Ieva R, Ferraretti A, et al. Safety and feasibility of levosimendan administration in Takotsubo cardiomyopathy: a case series. Cardiovasc Ther. 2013; 31: e133-e137.
27. Ueyama T, Kasamatsu K, Hano T, et al. Emotional stress induces transient left ventricular hypocontraction in the rat via activation of cardiac adrenoceptors: a possible animal model of 'tako-tsubo' cardiomyopathy. Circ J. 2002; 66: 712-713.
28. Takano Y, Ueyama T, Ishikura F,. Azelnidipine, unique calcium channel blocker, could prevent stress-induced cardiac dysfunction like α·β blocker. J Cardiol. 2012; 60: 18-22.